Personalized Cancer Vaccine Shows Promise in Mount Sinai Trial
Personalized Cancer Vaccine Shows promise in Early Trials
Table of Contents
- Personalized Cancer Vaccine Shows promise in Early Trials
- Personalized Cancer Vaccine PGV001: Promising Results in Early Trials – Q&A
- What is PGV001?
- How Dose PGV001 Work?
- What are Neoantigens?
- What Types of Cancer is PGV001 Being Studied For?
- What Were the Key Findings of the Phase 1 Clinical Trial and What Do the Results Indicate About PGV001?
- What are the Limitations of the phase 1 Trial?
- What is the Next Step in the Research and Development of PGV001?
- How Does PGV001 Differ From Other Cancer Immunotherapies?
- PGV001 Clinical trial: Key Outcomes
- Who is Leading the Research on PGV001?
new York,NY – 2025-03-17 – Researchers are making strides in the fight against cancer with innovative approaches like personalized cancer vaccines.A recent study at the Icahn School of Medicine at Mount Sinai has shown promising results for a new type of personalized multi-peptide neoantigen cancer vaccine, called PGV001.
PGV001: A Personalized Approach to Cancer Treatment
The phase 1 trial, lead by Nina Bhardwaj, MD, PhD, Ward-Coleman Chair in Cancer Research and Director of the Vaccine and cell Therapy Laboratory, represents a notable step forward in developing effective cancer treatments. The vaccine uses multiple peptides (amino acid sequences) to stimulate the body’s immune system, enabling it to recognise and attack cancer cells, ultimately preventing the disease from recurring. The findings are published in Cancer Discovery, a journal of the American Association for Cancer Research.
Overcoming Challenges in Cancer Immunotherapy
Immune-based therapies, including CAR T cells, bi-specific antibodies, antibody-drug conjugates, and immune checkpoint inhibitors (ICI), have revolutionized cancer treatment over the past decade. while these approaches have improved outcomes,some patients do not respond or eventually develop resistance. Personalized cancer vaccines, like PGV001, aim to address these challenges by training the immune system to identify unique cancer mutations, known as neoantigens, and mount a stronger, more targeted response.
How PGV001 Works
PGV001 is designed to be tailored to each patient’s unique cancer profile. Scientists employ advanced tools to identify neoantigens—tiny changes in cancer cells that are not present in healthy cells.The vaccine then instructs the immune system to target these specific changes, resulting in a more personalized and precise treatment approach. Unlike tumor-associated antigens, neoantigens are not subject to central tolerance, allowing them to trigger a robust immune response against cancer cells.
We wanted to develop cancer vaccines that can stop cancer from coming back in patients who are at high risk of recurrence.This study shows that making personalized cancer vaccines is possible and safe.
Dr. Bhardwaj
Dr. Bhardwaj further noted,
This is a phase 1 study with a small group of patients (n = 13) with a variety of cancers (non-small cell lung cancer, head and neck cancer, urothelial cancer, breast cancer and multiple myeloma), but it’s an exciting step toward using the immune system to help people live cancer-free, longer.
Dr. Bhardwaj
Study Results and Future Directions
The study involved patients who had already undergone standard cancer treatments but remained at high risk of disease recurrence. Scientists analyzed tumor and germline sequencing data using a computational platform to select the most promising neoantigens for each patient. The vaccine was formulated with carefully chosen peptide sequences encoding neoantigens to optimize immune activation.
Early results indicate that PGV001 did not cause serious side effects. At the five-year follow-up, six of the 13 patients treated were still alive, and three of those six were tumor-free. The vaccine also enhanced the immune system’s ability to respond to the cancer, suggesting it may help prevent disease recurrence.
| Outcome | Number of Patients |
|---|---|
| total Patients Treated | 13 |
| Patients Surviving at 5-Year Follow-Up | 6 |
| Tumor-Free Survivors | 3 |
Mount Sinai scientists plan to continue studying PGV001 in larger patient groups and exploring its potential in combination with other cancer treatments. Data from this phase 1 study have led to three additional PGV001 trials, including one in newly diagnosed glioblastoma, one in urothelial cancer in combination with an ICI, and another in prostate cancer.
Ongoing Research and Support
Multiple researchers from the Icahn school of Medicine at Mount Sinai contributed to this research, including Mansi Saxena, PhD, Thomas Marron, MD, PhD, Philip friedlander, MD, PhD, and Sayali Onkar, PhD. The study received support from the National Cancer Institute of the National Institutes of Health, the Cancer Research Institute, the Parker Institute of Cancer Immunotherapy, and industry partners.
Personalized Cancer Vaccine PGV001: Promising Results in Early Trials – Q&A
This article addresses key questions about a personalized cancer vaccine, PGV001, which has shown promise in early clinical trials. It dives into how the vaccine works, its potential benefits, and future research directions.
What is PGV001?
PGV001 is a novel, personalized multi-peptide neoantigen cancer vaccine developed by researchers at the Icahn School of Medicine at Mount Sinai. It’s designed to stimulate the body’s immune system to recognize and attack cancer cells, thereby preventing disease recurrence.
Related searches: personalized cancer vaccine, neoantigen vaccine, cancer immunotherapy
How Dose PGV001 Work?
PGV001 is tailored to each patient’s unique cancer profile. The process involves:
- Identifying Neoantigens: Scientists use advanced tools to identify neoantigens, which are unique mutations present in cancer cells but not in healthy cells.
- Vaccine Creation: The vaccine is then formulated with carefully selected peptide sequences encoding these neoantigens.
- Immune System Activation: PGV001 instructs the immune system to target these specific neoantigens, triggering a robust and targeted response against cancer cells. Unlike tumor-associated antigens, neoantigens are not subject to central tolerance, allowing them to trigger a strong immune response against cancer cells.
Related searches: neoantigen identification, personalized cancer treatment, mechanism of action cancer vaccine
What are Neoantigens?
Neoantigens are tiny changes or mutations found on the surface of cancer cells that are not present in normal, healthy cells. Because thay are unique to the cancer, they can be targeted by the immune system without harming healthy tissue. This makes them ideal targets for personalized cancer vaccines.
Related searches: what are neoantigens in cancer, neoantigen definition, neoantigen cancer therapy
What Types of Cancer is PGV001 Being Studied For?
In the phase 1 trial, PGV001 was studied in a small group of patients with a variety of cancers, including:
Non-small cell lung cancer
head and neck cancer
Urothelial cancer
Breast cancer
Multiple myeloma
Ongoing trials are exploring PGV001’s use in newly diagnosed glioblastoma, urothelial cancer (in combination with an immune checkpoint inhibitor), and prostate cancer.
Related searches: PGV001 clinical trials, cancer vaccine types, cancer vaccine research
What Were the Key Findings of the Phase 1 Clinical Trial and What Do the Results Indicate About PGV001?
The phase 1 trial showed promising early results:
Safety: PGV001 did not cause any serious side effects.
Survival: At the five-year follow-up, 6 out of 13 patients were still alive.
Tumor-Free Status: 3 out of the 6 surviving patients were tumor-free.
Immune response: The vaccine enhanced the immune system’s ability to respond to the cancer, suggesting it may help prevent disease recurrence.
These results indicate that personalized cancer vaccines like PGV001 are possible and safe and can elicit anti-tumor immunity.
Related searches: PGV001 phase 1 trial results, cancer vaccine success rate, cancer vaccine side effects
What are the Limitations of the phase 1 Trial?
Key limitations include:
Small Sample size: The study involved only 13 patients, which limits the generalizability of the findings.
Variety of Cancers: The patients had different types of cancer, making it challenging to draw specific conclusions for each cancer type.
Early-Stage Trial: as a phase 1 trial, the primary focus was on safety, with limited data on efficacy.
Related searches: limitations of phase 1 clinical trials, cancer vaccine challenges, PGV001 future studies
What is the Next Step in the Research and Development of PGV001?
Mount Sinai scientists plan to continue studying PGV001 in larger patient groups. They are also exploring its potential in combination with other cancer treatments, such as immune checkpoint inhibitors (ICIs).Data from the phase 1 study have led to three additional PGV001 trials, including studies in glioblastoma, urothelial cancer (with ICI), and prostate cancer.
Related searches: cancer vaccine future,combining cancer therapies,PGV001 clinical trial updates
How Does PGV001 Differ From Other Cancer Immunotherapies?
PGV001 differs from other immunotherapies like CAR T-cells,bi-specific antibodies,antibody-drug conjugates,and immune checkpoint inhibitors (ICIs) in its personalized approach.Rather of targeting general cancer mechanisms, it trains the immune system to identify and attack unique mutations (neoantigens) specific to each patient’s cancer, perhaps leading to a more targeted and effective response.
Related searches: cancer immunotherapy types, personalized vs non-personalized cancer treatment, CAR T-cell therapy vs cancer vaccine
PGV001 Clinical trial: Key Outcomes
| Outcome | Number of Patients |
| —————————————- | —————— |
| Total Patients Treated | 13 |
| Patients Surviving at 5-Year Follow-Up | 6 |
| Tumor-Free Survivors | 3 |
Who is Leading the Research on PGV001?
The phase 1 trial was led by Nina bhardwaj, MD, PhD, Ward-Coleman chair in Cancer Research and Director of the Vaccine and Cell Therapy Laboratory at the Icahn School of Medicine at Mount Sinai. Multiple researchers from the Icahn School of Medicine at Mount Sinai contributed to this research, including Mansi Saxena, PhD, Thomas Marron, MD, phd, Philip Friedlander, MD, PhD, and Sayali Onkar, PhD.
Related searches: Nina Bhardwaj cancer research, Mount Sinai cancer vaccine program, cancer vaccine researchers*